Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,301,882
  • Shares Outstanding, K 37,692
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,900 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 30.29
Trade AXSM with:

Options Overview Details

View History
  • Implied Volatility 137.96%
  • Historical Volatility 63.94%
  • IV Percentile 81%
  • IV Rank 77.96%
  • IV High 162.24% on 11/04/21
  • IV Low 52.08% on 01/20/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 1,562
  • Volume Avg (30-Day) 2,865
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 51,067
  • Open Int (30-Day) 44,685

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.99
  • Number of Estimates 7
  • High Estimate -0.87
  • Low Estimate -1.13
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.62 +5.89%
on 11/30/21
44.83 -22.95%
on 11/08/21
-3.96 (-10.29%)
since 10/29/21
3-Month
24.05 +43.62%
on 08/31/21
44.83 -22.95%
on 11/08/21
+10.16 (+41.67%)
since 08/30/21
52-Week
19.38 +78.22%
on 08/19/21
87.24 -60.41%
on 12/22/20
-40.64 (-54.06%)
since 11/27/20

Most Recent Stories

More News
How Much Upside is Left in Axsome (AXSM)? Wall Street Analysts Think 144%

The average of price targets set by Wall Street analysts indicates a potential upside of 143.7% in Axsome (AXSM). While the effectiveness of this highly sought-after metric is questionable, the positive...

AXSM : 34.54 (+0.58%)
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

AXSM : 34.54 (+0.58%)
SYBX : 2.49 (+2.89%)
GRTS : 13.20 (+25.71%)
FULC : 14.50 (+1.19%)
Axsome: Q3 Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Monday reported a loss of $34.9 million in its third quarter.

AXSM : 34.54 (+0.58%)
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...

AXSM : 34.54 (+0.58%)
Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More

Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.

RDUS : 16.46 (+0.37%)
AXSM : 34.54 (+0.58%)
EDIT : 32.66 (+4.48%)
VTRS : 12.31 (-1.68%)
Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome...

AXSM : 34.54 (+0.58%)
Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

$100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:...

AXSM : 34.54 (+0.58%)
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...

AXSM : 34.54 (+0.58%)
Pre-Market Brief: U.S. Stocks Set to Open Higher as Inflation Concerns Ease

Morning Markets Dec S&P 500 futures this morning shook off overnight losses and are up +0.41. Stock index futures pushed higher this morning after U.S. Aug consumer prices rose less than expected, easing...

KERN : 2.32 (-1.69%)
ORCL : 90.74 (-2.37%)
ANGI : 9.61 (+1.05%)
MP : 43.94 (-3.15%)
OPEN : 15.84 (-1.86%)
JCS : 3.04 (-4.10%)
FIGS : 33.24 (-0.66%)
AXSM : 34.54 (+0.58%)
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...

AXSM : 34.54 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 37.27
2nd Resistance Point 35.95
1st Resistance Point 35.25
Last Price 34.54
1st Support Level 33.23
2nd Support Level 31.91
3rd Support Level 31.21

See More

52-Week High 87.24
Fibonacci 61.8% 61.32
Fibonacci 50% 53.31
Fibonacci 38.2% 45.30
Last Price 34.54
52-Week Low 19.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar